Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our Understanding of Disease Progression

Por um escritor misterioso

Descrição

Through exclusive partnerships with three medical society registries in ophthalmology, neurology and urology, Verana Health has access to EHR data from more than 90 million de-identified patients and 20,000 clinicians. Our VeraQ® population health data engine–which is clinician-directed and enhanced by artificial intelligence–ingests, de-identifies, links and curates EHR data.
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our Understanding of Disease Progression
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Discoveries in Health Policy: March 2023
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Fellows in Training Section - American College of Cardiology
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Keyword:telemedicine platforms - FasterCapital
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Join us on July 26 - eCOA/ePRO Webinar by Clario - Questex
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Verana Health on LinkedIn: RWE for Post-Approval Studies
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Resources Fierce Pharma
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Keyword:telemedicine platforms - FasterCapital
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
Season 4 – Paddy Padmanabhan
Fierce Biotech Webinar Summary: Unlocking EHR Data to Improve Our  Understanding of Disease Progression
10.03.23 FDA flags 'systemic bias' in Amgen Lumakras trial; Radiopharma deal buzz as Lilly drops $1.4B on Point, Novartis' Dx interest decays - Questex
de por adulto (o preço varia de acordo com o tamanho do grupo)